All companies
Visit website
SynergyMed Cancer Treatment Technology
OperatingSynergyMed Devices Inc.
Healthcare · Technology · Founded 2019
Ground breaking cancer treatment: Tumors vanish within feww days
Valuation cap ⓘ
$16.0M
As of Apr 2025 · from SYNERGYMED CANCER TREATMENT TECHNOLOGY Future Equity SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$0
Across 1 round since 2024
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its source$0
−$21K
2022
$0
−$23K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$21,499
-$23,178
Taxes paid
$0
$0
Balance sheet
Cash
$65,920
$40,984
Accounts receivable
$0
$0
Total assets
$69,991
$48,713
Short-term debt
$0
$1,900
Long-term debt
$0
$0
Total liabilities
$0
$1,900
Other
Headcount
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$16.0M
Valuation cap
SYNERGYMED CANCER TREATMENT TECHNOLOGY Future Equity SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised — / $1.2MValuation cap $16M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001811959
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.